I agree. SGen's pps from day to day is inconsequential ... or even week to week ... as we are nuts to sell shares unless our baby needs new shoes. In fact, when the pps dips, it presents a buying opportunity to add shares.
It appears that buying opportunities are created when there is confusion among the investors. Recently, it was revealed that there were 1-2 deaths during a trial about 20 months ago. SGen's pps dipped by 9 within about 10 days. (I suspect that the deaths had nothing to do with their medication. If so, there would have been publicity long ago.) I was not able to take advantage of it, but my brother did.
I suspect the small dip the past few days has been because of the misunderstanding about the lifting of the 16 cycle limitation. RedHot and one other poster both had pointed out that Clay had announced that this limitation had already been lifted. There was no further need for the FDA to discuss it.